CUR vs. COEP, ONVO, CHRO, BCDA, TVGN, GENE, SNTI, SRNE, PMCB, and APTO
Should you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include Coeptis Therapeutics (COEP), Organovo (ONVO), Chromocell Therapeutics (CHRO), BioCardia (BCDA), Tevogen Bio (TVGN), Genetic Technologies (GENE), Senti Biosciences (SNTI), Sorrento Therapeutics (SRNE), PharmaCyte Biotech (PMCB), and Aptose Biosciences (APTO). These companies are all part of the "medical" sector.
Coeptis Therapeutics (NASDAQ:COEP) and Neuralstem (NASDAQ:CUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment.
Neuralstem has higher revenue and earnings than Coeptis Therapeutics.
Coeptis Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 733.33%. Given Neuralstem's higher probable upside, analysts clearly believe Coeptis Therapeutics is more favorable than Neuralstem.
Coeptis Therapeutics has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -39,417.64%. Coeptis Therapeutics' return on equity of -170.51% beat Neuralstem's return on equity.
13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 38.3% of Neuralstem shares are owned by institutional investors. 21.5% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 5.4% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Coeptis Therapeutics had 4 more articles in the media than Neuralstem. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 0 mentions for Neuralstem. Neuralstem's average media sentiment score of 0.00 equaled Coeptis Therapeutics'average media sentiment score.
Neuralstem received 273 more outperform votes than Coeptis Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Coeptis Therapeutics an outperform vote while only 66.83% of users gave Neuralstem an outperform vote.
Coeptis Therapeutics has a beta of -0.92, suggesting that its stock price is 192% less volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.
Summary
Coeptis Therapeutics and Neuralstem tied by winning 7 of the 14 factors compared between the two stocks.
Get Neuralstem News Delivered to You Automatically
Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neuralstem Competitors List
Related Companies and Tools
